Omni Bio Pharma names Bruce Schneider as new CEO
Omni Bio is involved in developing alternative uses of Alpha-1 antitrypsin (AAT), designed for treating various indications, as well as recombinant forms of AAT. Prior to joining the
Bristol Myers Squibb (BMS) is set to merge its separate research and development (R&D) departments into a single entity, effective from 1 January 2027.
Solithromycin, the company’s fluoroketolide antibiotic candidate, is designed for treating patients with community-acquired bacterial pneumonia (CABP). The study, which will enroll approximately 800 patients with PORT-II to PORT-IV